ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

HOWL Werewolf Therapeutics Inc

5.54
-0.18 (-3.15%)
Última actualización: 13:53:45
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Werewolf Therapeutics Inc HOWL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.18 -3.15% 5.54 13:53:45
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.72 5.52 5.84 5.72
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202406:00GLOBEWerewolf Therapeutics Reports First Quarter 2024 Financial..
24/4/202409:05GLOBEWerewolf Therapeutics Announces WTX-124 Clinical Abstract..
23/4/202407:00GLOBEWerewolf Therapeutics Presents First Preclinical Data..
05/4/202415:30GLOBEWerewolf Therapeutics Presents Preclinical Results..
04/4/202415:30GLOBEWerewolf Therapeutics to Present First-of-Its-Kind Data..
07/3/202406:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202406:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202406:11EDGAR2Form 8-K - Current report
07/3/202406:00GLOBEWerewolf Therapeutics Reports Fourth Quarter and Full Year..
06/3/202407:00GLOBEWerewolf Therapeutics to Present at the 2024 Leerink..
05/3/202415:30GLOBEWerewolf Therapeutics Announces Upcoming Presentations at..
09/2/202415:39EDGAR2Form 8-K - Current report
09/2/202415:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/1/202407:08EDGAR2Form 8-K - Current report
04/1/202418:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202418:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202416:00EDGAR2Form 8-K - Current report
04/1/202415:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:05GLOBEWerewolf Therapeutics Appoints Michael Atkins, M.D., to its..
22/11/202306:00GLOBEWerewolf Therapeutics to Present at the Evercore ISI..
14/11/202315:34EDGAR2Form 8-K - Current report
14/11/202315:25GLOBEWerewolf Therapeutics Reports Third Quarter 2023 Financial..
03/11/202306:05EDGAR2Form 8-K - Current report
03/11/202306:00GLOBEWerewolf Therapeutics Presents Preliminary Monotherapy Data..
31/10/202308:00GLOBEWerewolf Therapeutics to Present Clinical and Preclinical..
27/9/202308:00GLOBEWerewolf Therapeutics Announces Upcoming Presentations at..
18/9/202306:00EDGAR2Form 8-K - Current report
11/9/202315:05GLOBEWerewolf Therapeutics to Host KOL Event Highlighting IL-2..
05/9/202315:05GLOBEWerewolf Therapeutics to Participate in Upcoming Investor..
24/8/202313:00APSBiotech Soars On New Price Target And Analyst Rating
10/8/202306:16EDGAR2Form 8-K - Current report
10/8/202306:10GLOBEWerewolf Therapeutics Reports Second Quarter 2023 Financial..
10/8/202306:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/6/202306:00GLOBEWerewolf Therapeutics to Present at the Jefferies Healthcare..
11/5/202306:00GLOBEWerewolf Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock